logo
  

AstraZeneca's Lynparza Granted Priority Review In U.S. For High-risk Early Breast Cancer

AstraZeneca Plc. (AZN.L,AZN) said that its supplemental New Drug Application or sNDA for Lynparza or olaparib has been granted Priority Review in the US for the adjuvant treatment of patients with BRCA-mutated or BRCAm HER2-negative high-risk early breast cancer who have already been treated with chemotherapy either before or after surgery.

The Prescription Drug User Fee Act date, the FDA action date for their regulatory decision, is during the first quarter of 2022.

Lynparza is being jointly developed and commercialized by AstraZeneca and Merck & Co., Inc.

The sNDA was based on results from the OlympiA Phase III trial. The results showed Lynparza demonstrated a statistically significant and clinically meaningful improvement in invasive disease-free survival (iDFS), reducing the risk of invasive breast cancer recurrence, second cancers or death by 42% versus placebo.

Lynparza is approved in the US, EU, Japan and several other countries for the treatment of patients with germline BRCAm, HER2-negative, metastatic breast cancer previously treated with chemotherapy based on results from the OlympiAD Phase III trial. In the EU, this indication also includes patients with locally advanced breast cancer.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Towson, Maryland-based DeWALT Industrial Tool Co. is recalling about 8,500 units of corded chain saws citing injury risks, the U.S. Consumer Product Safety Commission said. The recall involves DEWALT DWCS600, Type 1 18-inch 15-amp corded chain saws. They are yellow with a black handle and motor cover. The recall includes chain saws with date codes 2021 23-H5 to 2021 40-H5 only. Shares of Deutsche Bank AG were gaining around 5 percent in German trading and 4 percent in pre-market activity on the NYSE after the banking major reported Thursday significantly higher fourth-quarter net profit on tax benefit and higher revenues. Pre-tax profit, meanwhile, declined on increased expenses. Looking ahead, the company said it is on track to deliver 2022 targets and ambitions. Variety store chain Family Dollar is recalling around 38,300 units of beach loungers citing injury risk, the U.S. Consumer Product Safety Commission said. The recall involves beach lounge chairs with a white metal frame and either red or blue woven plastic fabric. The lounge chairs have a hang tag intended to be removed after purchase.
Follow RTT